Coronado Industries' Glaucoma Treatment ``PNT'' Soon To Be Introduced Into Great Britain; European Update.FOUNTAIN HILLS, Ariz. -- Coronado Industries, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Ophthalmic International, provided an update on its negotiations for additional distributors for its innovative Pneumatic Trabeculoplasty Device. As a precursor to signing a distribution agreement for the exclusive sale of Coronado Industries' patented glaucoma device in Great Britain Great Britain, officially United Kingdom of Great Britain and Northern Ireland, constitutional monarchy (2005 est. pop. 60,441,000), 94,226 sq mi (244,044 sq km), on the British Isles, off W Europe. The country is often referred to simply as Britain. - selected local ophthalmologists will be allowed to perform PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin treatments in their local hospitals and offices. To that end, Dr. Francesco Aspes, Coronado's Head of European Operations, will be traveling to Great Britain this week for initial discussions with these selected doctors. Dr. Aspes states, "As more and more PNT treatments are being performed successfully throughout Italy and Spain, the word gets out about what we're doing and the huge benefits of PNT in the total management of a glaucoma patient." Contracts for the exclusive distribution of Coronado's device are being negotiated at this time for France, German, Greece, Belgium and the U.K. Contracts for distribution outside of Europe are being handled by Dr. John Sharkey, Coronado's Director of Operations. "We have been contacted by interested companies from all over the world," said Dr. Sharkey. "I have calls from South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. , India, China, Australia and Canada." Richard Smith, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Coronado Industries states, "We are very happy with the addition of the contract for Poland last week with Meditherm and remain confident that we will be able to announce additional distributorships within the coming weeks." On another subject, anyone wishing to follow the article on PNT being published in the European Journal of Ophthalmology next month can go to their website address: www.eur-j-ophthalmol.comOphthalmol.com/ejo/ "We are very happy with our progress thus far and are excited about the expansion of our sales contracts in our future," Richard went on to say. Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary as well as for the treatment of ocular hypertension. Forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion